Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company whose news flow centers on gastrointestinal diseases, infectious diseases and oncology. Company press releases furnished on Form 6-K highlight both commercial developments around its FDA-approved H. pylori therapy Talicia® and clinical and preclinical updates from its late-stage pipeline, including opaganib (ABC294640), RHB-102 (Bekinda®), RHB-204 and RHB-107 (upamostat).
Investors following RDHL news can expect regular updates on Talicia’s commercialization, such as U.S. co-commercialization with Cumberland Pharmaceuticals, ex-U.S. licensing deals in regions like the Middle East, and milestone and royalty payments from international launches. RedHill also issues news on Talicia’s clinical positioning, including its status as a first-line option in American College of Gastroenterology guidelines and its role as a low-dose rifabutin-based therapy designed to address H. pylori antibiotic resistance.
On the development side, RedHill’s news frequently covers pipeline data and regulatory plans. Examples include positive in vivo and clinical results for opaganib in oncology and viral indications, Phase 2 and Phase 3 outcomes for RHB-102 in gastroenteritis, gastritis and IBS-D, and plans for RHB-102 in GLP-1/GIP receptor agonist therapy-associated gastrointestinal side effects. Updates also describe RHB-107’s late-stage development in non-hospitalized symptomatic COVID-19 and RHB-204’s planned studies in Crohn’s disease and pulmonary nontuberculous mycobacteria disease.
RedHill’s news feed additionally reports on Nasdaq listing compliance matters, capital-raising activities, and legal proceedings, such as New York Supreme Court judgments and related enforcement steps in the Kukbo litigation. For readers tracking RDHL, this page aggregates these corporate, clinical, regulatory and legal announcements in one place, allowing a consolidated view of the company’s ongoing activities and disclosures.
RedHill Biopharma (Nasdaq: RDHL) has announced positive Phase 3 data for RHB-104, a triple antimicrobial therapy targeting Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease. The study, published in the journal Antibiotics, showed that RHB-104 plus standard of care (SoC) was 64% more effective than SoC alone. The primary endpoint of clinical remission at week 26 was achieved in 36.7% of RHB-104 patients compared to 22.4% of placebo patients (p=0.0048). The safety profile was similar to placebo. This data supports the hypothesis of a Mycobacterial basis for Crohn's disease and opens a potential new avenue for treatment. The Crohn's disease market was valued at over $13 billion in 2023.
RedHill Biopharma (Nasdaq: RDHL) has announced a significant financial restructuring through a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, , and HCR Redhill SPV, This agreement has resulted in:
1. A $9.9 million cash influx
2. Full control over an additional $0.74 million in a restricted account
3. An increase of $12.2 million in liabilities
4. A net balance sheet reduction of $2.3 million
5. Removal of the existing lien against Talicia®
6. Restoration of control over cash collections to RedHill
This restructuring aims to strengthen RedHill's cash position, enhance cash management, and allow the company to focus on R&D and commercial activities for future growth.
RedHill Biopharma (Nasdaq: RDHL) and Cosmo Technologies have mutually agreed to terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea. The initial agreement, established on October 17, 2019, will end on October 8, 2024. RedHill will cease all commercialization efforts for Aemcolo upon termination, with all rights reverting to Cosmo. Rick Scruggs, Chief Commercial Officer of RedHill, expressed gratitude for the collaboration with Cosmo.
RedHill Biopharma announced a new Chinese patent that covers the use of opaganib in combination with immune checkpoint inhibitors (ICIs) to induce an anti-cancer immune response, valid until 2040. This patent, issued by the Chinese National Intellectual Property Administration, reinforces opaganib's potential across various approved and in-development ICIs for a growing number of indications. ICIs, pivotal in cancer treatment, are projected to contribute to a global market exceeding $100 billion by 2028. Opaganib, an oral small molecule with proven safety and efficacy, is also in development for COVID-19, Ebola, and other conditions.
RedHill Biopharma announced a new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication, specifically against Ebola Virus, valid through 2035. The patent strengthens opaganib's global intellectual property portfolio, with studies indicating its effectiveness in treating Ebola and potential synergistic effects in combination with remdesivir. Opaganib, a twice-daily oral small molecule, is being developed for multiple indications, including COVID-19, acute respiratory distress syndrome, oncology, and U.S. government-sponsored countermeasures programs. It has shown safety, efficacy, resistance to viral mutations, and ease of administration, positioning it well for various scenarios including viral pandemics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.